Tesamorelin fat studies

Pituitary responses to tesamorelin

Tesamorelin resembles growth hormone-releasing hormone, the signal that prompts the pituitary gland to release growth hormone in pulses. Its chemical modification slows the rapid breakdown of the natural signal. Growth hormone then increases the liver’s production of IGF-1, a growth factor.

The small study in 13 healthy men helps explain this action. Over two weeks, tesamorelin increased mean overnight growth hormone and raised IGF-1, while fasting glucose and insulin-stimulated glucose uptake showed no significant change.

The restraint of that experiment suits my taste. It investigated hormone release and insulin sensitivity over a short period. A claim about general rejuvenation would carry it far beyond what was measured. The larger clinical interest concerns visceral fat, the fat stored around abdominal organs.

Tesamorelin scan findings

In a six-month trial of 50 adults with HIV taking antiretroviral treatment, 28 participants received tesamorelin and 22 received placebo. The treatment effect on visceral fat was -42 cm², measured as area on a scan, and liver fat also decreased.

That unit deserves its space in the sentence. A change in square centimetres on an abdominal scan measures something different from kilograms on a scale. The result is clinically interesting on its own terms.

The 2026 meta-analysis of five randomized trials found reductions in visceral fat, trunk fat and hepatic fat fraction, alongside increased lean body mass, in HIV-associated lipodystrophy. Lean mass includes more than skeletal muscle, so the increase cannot simply be renamed muscle growth. No serious adverse events were reported in that analysis; longer-term safety still needs attention.

Stopping tesamorelin

The 52-week tesamorelin programme reported sustained visceral-fat reduction of -18% from baseline during treatment. Visceral fat reaccumulated after discontinuation; the clinical literature describes its return within weeks.

This makes the attractive idea of a brief corrective course difficult to defend. I judge the durability question as seriously as the initial scan result. Continued benefit depends on continued treatment, with the demands and uncertainties that entails.

Adding another peptide to the discussion does nothing to settle that issue. The trials above studied tesamorelin in a defined clinical population. They do not establish that a combination with MOTS-c or tirzepatide would preserve the result after treatment ends.

Tesamorelin’s approved use

Tesamorelin was approved in the United States in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. General weight loss, anti-aging and other proposed uses fall outside that approved indication. Large trials have not established the same benefit in the general population.

Growth-hormone stimulation raises IGF-1, so active malignancy is a contraindication. Trials around a year long found no excess malignancy signal, leaving longer-term cancer safety uncertain. Glucose changes also matter, particularly in people already near diabetes levels. The short healthy-men experiment cannot settle that longer question.

The LiverTox assessment considers tesamorelin an unlikely cause of clinically apparent liver injury and notes no attributable cases in trials. That is a reassuring finding about one kind of harm. It leaves the other cautions intact. WADA prohibits tesamorelin in sport, both during and outside competition.

For comparisons with mitochondrial research, the MOTS-c vs tesamorelin answer explains why these compounds cannot be treated as interchangeable ingredients.